SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-059136
Filing Date
2024-05-09
Accepted
2024-05-09 08:00:51
Documents
15
Period of Report
2024-05-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2413446d1_8k.htm   iXBRL 8-K 26263
2 EXHIBIT 99.1 tm2413446d1_ex99-1.htm EX-99.1 57414
6 GRAPHIC tm2413446d1_ex99-1img001.jpg GRAPHIC 24021
  Complete submission text file 0001104659-24-059136.txt   303572

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ewtx-20240509.xsd EX-101.SCH 3021
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ewtx-20240509_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ewtx-20240509_pre.xml EX-101.PRE 22363
18 EXTRACTED XBRL INSTANCE DOCUMENT tm2413446d1_8k_htm.xml XML 3679
Mailing Address 1715 38TH ST BOULDER CO 80301
Business Address 1715 38TH ST BOULDER CO 80301 720-262-7002
Edgewise Therapeutics, Inc. (Filer) CIK: 0001710072 (see all company filings)

IRS No.: 821725586 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40236 | Film No.: 24928679
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)